Stelo Becomes the First Over-the-Counter Glucose Biosensor in the U.S.

On March 5, 2024, Dexcom, Inc. announced that the FDA has cleared Stelo to become the first over-the-counter glucose biosensor in the United States.

Stelo, which is indicated for persons 18 and older, allows people with type 2 diabetes to benefit from continuous glucose monitoring (CGM) technology.

What is Stelo?

Stelo will be the first glucose biosensor in the U.S. cleared for use without a prescription.

Stelo is a compact, wearable sensor that is placed on the back of the upper arm and sends glucose data directly to the user’s smartphone.

CGM technology enables individuals with diabetes to better understand how different diets and activities affect their blood-sugar levels.

When will Stelo be available?

Stelo will be available for purchase online without a prescription beginning in summer 2024.

To learn more and verify eligibility for Dexcom G7, visit https://www.dexcom.com/en-us/stelo.